Absorbable mesh sling prevents radiation-induced bowel injury during "sandwich" chemoradiation for rectal cancer.
OBJECTIVE
Absorbable mesh slings can prevent radiation-induced bowel injury when adjuvant pelvic radiotherapy is given in the early postoperative period. We hypothesized that the mesh sling technique is similarly effective during "sandwich" sequence adjuvant chemoradiation.


METHODS
Retrospective review.


METHODS
Tertiary care comprehensive cancer center.


METHODS
Nonrandomized series of 19 consecutive patients who underwent abdominoperineal resection and received postoperative sandwich sequence chemoradiation at Roswell Park Cancer Institute, Buffalo, NY, between January 1994 and September 1999.


METHODS
Twelve patients had an absorbable mesh sling placed at the completion of abdominoperineal resection. Seven patients did not have an absorbable mesh sling placed.


METHODS
Radiotherapy dose and gastrointestinal toxic effects.


RESULTS
All 12 patients in the "mesh" group were able to receive full-dose radiotherapy with tumor bed boost (total dose, 54 Gy, 11 patients; 59.4 Gy, 1 patient). Only 3 of 7 patients in the "no mesh" group were able to receive a tumor bed boost (total dose, 46.8 Gy, 1 patient; 50.4 Gy, 3 patients; 54 Gy, 3 patients). Acute gastrointestinal toxic effects were minimal in the mesh group (grade 1, 10 patients; grade 2, 2 patients) compared with the no mesh group (grade 2, 6 patients; grade 3, 1 patients). None of the patients in the mesh group have shown evidence of late gastrointestinal toxic effects. One patient in the no mesh group required surgery for complications of chronic radiation enteritis.


CONCLUSIONS
The protective effects of an absorbable mesh sling extend beyond the life expectancy of the mesh itself. Sandwich sequence chemoradiation should not preclude the use of the mesh sling technique.
Waddell
B E
BE
Division of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton streets, Buffalo, NY 14263, USA. nicholas.petrelli@roswellpark.org
Lee
R J
RJ
Rodriguez-Bigas
M A
MA
Weber
T K
TK
Petrelli
N J
NJ
D000230:Adenocarcinoma / Q000628:therapy*; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D004307:Dose-Response Relationship, Radiation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007421:Intestine, Small / Q000528:radiation effects*; D008297:Male; D008875:Middle Aged; D011832:Radiation Injuries / Q000209:etiology / Q000517:prevention & control*; D011878:Radiotherapy / Q000379:methods; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects*; D012004:Rectal Neoplasms / Q000628:therapy*; D012016:Reference Values; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D013526:Surgical Mesh; D016896:Treatment Outcome
D005472:Fluorouracil